Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Elena G Chiorean"'
Autor:
Hui Cai, Elena G Chiorean, Michael V Chiorean, Douglas K Rex, Bruce W Robb, Noah M Hahn, Ziyue Liu, Patrick J Loehrer, Marietta L Harrison, Yan Xu
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e57081 (2013)
Only in recent years have phospholipase A2 enzymes (PLA2s) emerged as cancer targets. In this work, we report the first detection of elevated PLA2 activities in plasma from patients with colorectal, lung, pancreatic, and bladder cancers as compared t
Externí odkaz:
https://doaj.org/article/c628a348113c433b9bdfd1c4f18d630e
Autor:
Xiaoqi Liu, Elena G. Chiorean, Tony Hazbun, Timothy L. Ratliff, Stephen F. Konieczny, Bennett D. Elzey, Shihuan Kuang, Steven J. Rice, X. Shawn Liu, Bing Song
PDF file - 30k, knock-down of cFos and MDR1 by RNAi in gemcitabine-resistant cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3dfac391ca28a5a7bf5dae7ecd9cfa1
https://doi.org/10.1158/1535-7163.22499431
https://doi.org/10.1158/1535-7163.22499431
Autor:
Xiaoqi Liu, Elena G. Chiorean, Tony Hazbun, Timothy L. Ratliff, Stephen F. Konieczny, Bennett D. Elzey, Shihuan Kuang, Steven J. Rice, X. Shawn Liu, Bing Song
PDF file - 67K, Orc2-A and Hbo1-A mutant cells are sensitive to gemcitabine treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d9362b4e5b84fcd6e4d70b9984c99a9
https://doi.org/10.1158/1535-7163.22499434.v1
https://doi.org/10.1158/1535-7163.22499434.v1
Autor:
Xiaoqi Liu, Elena G. Chiorean, Tony Hazbun, Timothy L. Ratliff, Stephen F. Konieczny, Bennett D. Elzey, Shihuan Kuang, Steven J. Rice, X. Shawn Liu, Bing Song
Although gemcitabine is the standard chemotherapeutic drug for treatment of pancreatic cancer, almost all patients eventually develop resistance to this agent. Previous studies identified Polo-like kinase 1 (Plk1) as the mediator of gemcitabine resis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33a5751180a1e246bc6ff812f3a08aa9
https://doi.org/10.1158/1535-7163.c.6536140.v1
https://doi.org/10.1158/1535-7163.c.6536140.v1
Autor:
Xiaoqi Liu, Elena G. Chiorean, Tony Hazbun, Timothy L. Ratliff, Stephen F. Konieczny, Bennett D. Elzey, Shihuan Kuang, Steven J. Rice, X. Shawn Liu, Bing Song
PDF file - 102K, Gemcitabine-resistant tumors are sensitive to inhibition of Plk1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::468e89e99f0c925b32c04325616baf85
https://doi.org/10.1158/1535-7163.22499437
https://doi.org/10.1158/1535-7163.22499437
Autor:
Xiaoqi Liu, Elena G. Chiorean, Tony Hazbun, Timothy L. Ratliff, Stephen F. Konieczny, Bennett D. Elzey, Shihuan Kuang, Steven J. Rice, X. Shawn Liu, Bing Song
PDF file - 17K, The IC50 values of Gemcitabine in Pancreatic cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d24953e48a8a560db2b341e0386fe993
https://doi.org/10.1158/1535-7163.22499425.v1
https://doi.org/10.1158/1535-7163.22499425.v1
Autor:
Xiaoqi Liu, Elena G. Chiorean, Tony Hazbun, Timothy L. Ratliff, Stephen F. Konieczny, Bennett D. Elzey, Shihuan Kuang, Steven J. Rice, X. Shawn Liu, Bing Song
PDF file - 44K, Inhibition of Plk1 sensitizes cells to gemcitabine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aac0916d9fade1fa35b4dbe6764d40f5
https://doi.org/10.1158/1535-7163.22499440.v1
https://doi.org/10.1158/1535-7163.22499440.v1
Autor:
Xiaoqi Liu, Elena G. Chiorean, Tony Hazbun, Timothy L. Ratliff, Stephen F. Konieczny, Bennett D. Elzey, Shihuan Kuang, Steven J. Rice, X. Shawn Liu, Bing Song
PDF file - 88K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::068eb7509114e40e4563919a2e5e35b8
https://doi.org/10.1158/1535-7163.22499428
https://doi.org/10.1158/1535-7163.22499428
Autor:
Monica Mita, Bruce A. Silver, Cheryl Eaton, Lisa Iacono, Jochem Gokemeijer, Eric Furfine, Kamalesh Sankhala, Alain C. Mita, Elena G. Chiorean, Amita Patnaik, Kyri Papadopoulos, Christopher J. Sweeney, Anthony W. Tolcher
Purpose: To determine the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of CT-322 (BMS-844203), a VEGFR-2 inhibitor and the first human fibronectin domain–based targeted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c3210a253c35d84e41216bfa935a3c6
https://doi.org/10.1158/1078-0432.c.6519701.v1
https://doi.org/10.1158/1078-0432.c.6519701.v1
Autor:
Wells A. Messersmith, Charles Zacharchuk, Kathleen Turnbull, Eric Leip, Poe-Hirr Hsyu, Nathalie Bardy-Bouxin, Shefali Agarwal, Richat Abbas, Gregory M. Springett, Elena G. Chiorean, Philip J. Gold, Mitesh J. Borad, Barbara J. Gitlitz, Mansoor N. Saleh, Smitha S. Krishnamurthi, Adil I. Daud
PDF file - 89K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f4587c6678ceb7f5636d4a877514e37
https://doi.org/10.1158/1078-0432.22444170
https://doi.org/10.1158/1078-0432.22444170